Optime Care Offers Patient-First Humatin Total Care Program, Maximizes Therapeutic Benefits of Humatin™ for Treatment of Intestinal Amebiasis

Optime Care, a nationally recognized pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, announces the availability of Humatin™ (paromomycin sulfate) exclusively through Humatin Total Care. This patient-first drug management program optimizes the benefits of Humatin for patients with acute and chronic intestinal amebiasis and as an adjunctive therapy for management of hepatic coma. Look for a provider toolkit available soon.

"Intestinal amebiasis is a parasitic infection of the intestines caused by a protozoan Entamoeba histolytica that can affect anyone, although it is more common in people who live in or who have traveled to tropical areas with poor sanitary conditions," says Donovan Quill, president and CEO, Optime Care. "People become infected by ingesting contaminated food or water, or cysts (eggs) through contact with fecal matter of a person infected with the protozoan."

Of those infected, approximately 10-20% become sick. Symptoms include loose stool, stomach pain and abdominal cramping, which usually develop within 2-4 weeks and are generally mild.

Optime Care's patient-first approach can ensure care continuity across the entire patient journey with robust communication to yield rich data that clinicians can use to make more informed decisions and improve the overall patient experience.

Quill concludes, "Our dedicated Humatin Total Care coordinator works with insurance companies to verify coverage and reimbursement benefits, provide access to financial assistance and arrange drug delivery for the patient."

To schedule a lunch and learn, contact Humatin Total Care Team at 1-844-486-2846.

About Optime Care

Optime Care, Inc. is a nationally recognized pharmacy, distribution and patient management organization offering a suite of comprehensive services tailored to maximize the therapeutic opportunities for the treatment of orphan and rare disorders. Our management team has previously partnered in the launch and management of more than 40 orphan products and programs and consistently implemented the best brand programs for the community. Our experience with small patient populations makes us uniquely qualified to help every stakeholder group impacted by these disorders. Optime Care has dual-accreditation from the Utilization Review Accreditation Commission (URAC) for compliance with specialty pharmacy and the Accreditation Commission for Health Care (ACHC) for specialty pharmacy services that demonstrate a commitment to providing quality care and services to consumers. https://www.optimecare.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005033/en/